ARS Pharma discloses $228M cash; neffy investor day presentation published

ARS Pharmaceuticals, Inc.

Cash and short-term investments of ~$228M as of December 31, 2023.
Updated corporate presentation for neffy (epinephrine nasal spray) shared with investors.
No additional financial results or forward guidance provided in the 8-K.

item 2.02 item 7.01 item 9.01

ARS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-061842

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.